We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Karyopharm Therapeutics Inc | NASDAQ:KPTI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 1.87% | 1.09 | 1.05 | 1.09 | 1.11 | 1.02 | 1.05 | 1,130,309 | 00:13:38 |
From May 2023 to May 2024
By Ben Glickman
Karyopharm Therapeutics said Monday it received Fast Track Designation from the U.S. Food and Drug Administration for its treatment for myelofibrosis.
The Newton, Mass.-based pharmaceutical company said selinexor is currently being tested in conjunction with ruxolitinib to treat a form of myelofibrosis, a rare form of blood cancer, in a Phase 3 study. The study was initiated last month.
Fast track status from the FDA is meant to speed up the development and review of treatments for serious and life-threatening conditions.
Top-line data from the Phase 3 study is expected in 2025.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 17, 2023 16:33 ET (20:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Karyopharm Therapeutics Chart |
1 Month Karyopharm Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
